Vulvar cancer surgery guided by HPV and p53 testing
Part of Cancer clinical trials.
This trial is for people with early-stage vulvar cancer that can be surgically removed. It looks at the cancer's HPV and p53 status to decide how much tissue to remove, aiming to reduce side effects while keeping the cancer away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have vulvar squamous cell carcinoma that has been confirmed by a biopsy.
- Your cancer is at an early stage (FIGO stage I or II) and has been removed with standard surgery.
- You are 18 years or older.
- You have not had radiation or chemotherapy for vulvar cancer before or after surgery.
- Your tumor is not the type that is HPV-negative and has normal p53 (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two immunotherapy drugs—nivolumab (given by IV) and imiquimod (a cream)—is safe and works in people with vulvar cancer that is hard to treat. The goal is to shrink the tumor before surgery, making it easier to remove.
This study is testing a new imaging tracer (a substance that helps see cancer on scans) on tissue samples from people with vulvar cancer. It aims to see if this tracer can help better identify cancer cells.
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
This Phase 2 study looks at how vulvar squamous cell cancer (SCC) spreads to the sentinel lymph node, and how findings may guide treatment. It focuses on specific early-stage tumor features and requires that cancer is found in the sentinel lymph node.
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
Hear when a new Vulvar Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.